Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Asubio Pharmaceuticals has reported that carperitide, a recombinant form of human atrial natriuretic peptide, significantly reduced cardiac death and re-hospitalization for heart failure in acute myocardial infarction, when used as an adjunct to percutaneous coronary intervention.
Subscribe to our email newsletter
In the independently conducted, large-scale, randomized, single-blind study by J-WIND in 603 patients, carperitide, when administered to acute myocardial infarction (AMI) patients after reperfusion treatment, was associated with a reduction in infarct size by 14.7%, reduction in reperfusion-related injuries by 25.9%, and statistically significant reductions in cardiac-related mortality and hospitalizations due to heart failure relative to the standard of care. Approximately 10% of patients on carperitide experienced hypotension. These results were consistent with other smaller clinical studies where carperitide was associated with treatment benefit when administered to patients with AMI.
Asubio is currently considering the licensing of this compound for further development in the US and Europe.
Bruce Reidenberg, senior director, clinical research at Asubio, said: “We believe that further development will demonstrate that carperitide can be a safe and effective adjunctive treatment for acute myocardial infarction.”